• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 10:30:29 AM ET
    $ALXN
    Major Pharmaceuticals
    Health Care
    Get the next $ALXN alert in real time by email
    SC 13G/A 1 tv0168-alexionpharmaceutical.htm SCHEDULE 13G/A alexionpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Alexion Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  015351109

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  015351109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    355,548

    7.  SOLE DISPOSITIVE POWER

    18,456,125

    8.  SHARED DISPOSITIVE POWER

    950,643

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    19,406,768

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.87%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Alexion Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    352 Knotter Drive
    Cheshire, Connecticut 06410

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    015351109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    19,406,768

      (b) Percent of Class:

    8.87%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  355,548

    (iii)  sole power to dispose of or to direct the disposition of:  18,456,125

    (iv)  shared power to dispose or to direct the disposition of:  950,643

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $ALXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moderna Set to Join S&P 500

      NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please

      7/15/21 7:01:00 PM ET
      $SPGI
      $ALXN
      $AZN
      $MRNA
      Finance: Consumer Services
      Finance
      Major Pharmaceuticals
      Health Care
    • Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

      – Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s

      7/15/21 4:05:00 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

      NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma

      7/14/21 8:00:00 PM ET
      $ALXN
      $NDAQ
      $HON
      Major Pharmaceuticals
      Health Care
      Investment Bankers/Brokers/Service
      Finance

    $ALXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alexion Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00

      5/5/21 6:41:15 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Credit Suisse resumed coverage on Alexion Pharma with a new price target

      Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00

      4/26/21 8:53:18 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Alexion Pharma downgraded by SVB Leerink

      SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform

      3/23/21 7:28:52 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ALXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4: COUGHLIN CHRISTOPHER J returned 42,347 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:54:11 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: FRIEDMAN PAUL A returned 12,840 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:51:08 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: SARIN ARADHANA returned 120,253 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:52:30 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/16/21 12:23:41 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/12/21 6:51:47 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/10/21 10:30:29 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $ALXN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.

      15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      8/2/21 9:02:07 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:08 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:53 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care